An interventional study of active rTMS of M1 and sham TMS in Spinal Cord Injury and Neuropathic Pain, sponsored by Ankara Etlik City Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Spinal Cord Injuries with a site in Turkey — 16 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · Turkey.
Among the 62 studies in Spinal Cord Injuries with a site in Turkey, this one is the 13th largest by planned enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2025, is one of 29 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 45th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →16 of the 62 studies in Spinal Cord Injuries with a site in Turkey are open now. Recruiting first, the newest first:
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Sites in Turkey
Ages 18+
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–65
Nuh Naci Yazgan University · Sites in Turkey
Ages 18–55
Istanbul Medeniyet University · Sites in Turkey
Ages 16+
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 39 is above the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 34 across the 31 interventional studies, 50 across the 31 observational. Of the 43 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 62 have an industry lead sponsor. The 10 most frequent:
Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Ankara Etlik City Hospital has 1 study filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
4 of the studies in Spinal Cord Injuries with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846410Istanbul Physical Medicine Rehabilitation Training and Research HospitalVirtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury | 2026-11 |
| NCT07849062Nuh Naci Yazgan UniversityRobot-Assisted Intensive Physiotherapy in Individuals With Spinal Cord Injury | 2027-02 |
| NCT07865338Gaziler Physical Medicine and Rehabilitation Education and Research HospitalPatterns of Rehabilitation After Spinal Cord Injury | 2027-03-30 |
| NCT07293780Ankara Etlik City HospitalEffect of TMS on Neuropathic Pain for Patients With Spinal Cord Injury | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 62 studies in Spinal Cord Injuries with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients will be randomly assigned to three groups using a randomization scheme: active primary motor cortex (M1) rTMS, active anterior cingulate cortex (ACC) rTMS, or sham M1 rTMS. Stimulation will be delivered using a Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, UK) with figure-of-eight active and sham coils or a double-cone coil, depending on the treatment group. All patients will receive 10 sessions of 5 Hz rTMS over two weeks under physician supervision. Stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of stimulation separated by 50-second intervals, delivering a total of 500 pulses. All patients will continue their conventional physical therapy programs throughout the study.
This study will be designed as a randomized, double-blind, sham-controlled clinical trial. Eligible patients will be randomly allocated to one of three groups using a computer-generated randomization sequence: active primary motor cortex (M1) repetitive transcranial magnetic stimulation (rTMS), active anterior cingulate cortex (ACC) rTMS, or sham M1 rTMS.
Stimulation will be performed at Etlik City Hospital and Ankara Gaziler Physical Medicine and Rehabilitation Training and Research Hospital using a Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK). Active and sham figure-of-eight coils will be used for M1 stimulation, while a double-cone coil will be used for ACC stimulation.
All participants will undergo 10 rTMS sessions over two consecutive weeks, with five sessions per week, under physician supervision. In the active and sham M1 groups, stimulation will target the lower extremity representation of the primary motor cortex using active or sham stimulation according to group allocation. In the active ACC group, stimulation will target the anterior cingulate cortex. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.
The study will employ a double-blind design in which participants and outcome assessors will remain unaware of treatment allocation throughout the study. The physician administering rTMS will be aware of group assignments but will not participate in outcome assessments. All participants will continue their conventional physical therapy programs throughout the intervention period.
This design aims to compare the effects of stimulation targeting different cortical regions on clinical outcomes while minimizing potential bias associated with treatment expectations and outcome assessment.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with 8- coil.
Device: active rTMS of M1
Active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision with double cone coil.
Device: active rTMS of anterior cingulate cortex
sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with sham 8 coil.
Device: sham TMS
Patients in the active primary motor cortex rTMS group will receive active rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with 8 coil. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.
Patients in the sham primary motor cortex rTMS group will receive sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with sham 8-coil. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.
Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision with double cone coil. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.
visual analog scale - daytime
The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".
Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
visual analog scale - night
The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".
Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
neuropathic pain scale
Neuropathic Pain Scale (NPS) will be used to assess the severity and characteristics of neuropathic pain. The scale consists of 10 items evaluating pain intensity, unpleasantness, and specific pain qualities, including sharp, burning, dull, cold, sensitive, and itchy sensations, as well as deep and superficial pain. Each item is scored from 0 to 10, with a total score ranging from 0 to 100. Higher scores indicate greater neuropathic pain severity.
Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
Beck Depression Inventory
Beck Depression Inventory (BDI) will be used to assess the severity of depressive symptoms. The inventory consists of 21 self-reported items evaluating cognitive, emotional, and somatic symptoms of depression. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater severity of depressive symptoms.
Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
Patient satisfaction
Patient satisfaction will be assessed using a 5-point Likert scale, ranging from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater patient satisfaction.
Time frame: End of treatment (week 2), 4 week after end of treatment (week 6), 12 week after end of treatment (week 14)
Plan to share: No — The data supporting this study's findings can be obtained from the corresponding author upon reasonable request.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for May 2027, 16 months after the start.
Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 16 months is below that.
Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2026 → May 2027 and completion Nov 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.